NEW OPPORTUNITIES LABORATORY DIAGNOSIS INSULIN RESISTANCE IN MYOCARDIAL INFARCTION
- Authors: Gruzdeva O.1, Uchasova E.1
-
Affiliations:
- Research Institute for Complex Issues of Cardiovascular Diseases, SB RAMS
- Issue: Vol 25, No 1 (2014)
- Pages: 79-83
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115972
- ID: 115972
Cite item
Open Access
Access granted
Abstract
Important risk factors for insulin resistance (IR) in myocardial infarction (MI), along with insulinemia and glycemia, is to increase the concentration of free fatty acids (FFA) and the imbalance in the system adipokines against deficiency of ghrelin in acute and early recovery periods of the disease. FFA and ghrelin are promising laboratory markers for stratifying the risk of IR in patients with MI
Full Text
About the authors
O. Gruzdeva
Research Institute for Complex Issues of Cardiovascular Diseases, SB RAMSCandidate of Medical Sciences Kemerovo
E. Uchasova
Research Institute for Complex Issues of Cardiovascular Diseases, SB RAMS
Email: evg.uchasova@yandex.ru
Candidate of Medical Sciences Kemerovo
References
- Lazzeri C., Sori A., Chiostri M. et al. Prognostic role of insulin resistance as assessed by homeostatic model assessment index in the acute phase of myocardial infarction in nondiabetic patients submitted to percutaneous coronary intervention // Eur. J. Anaesthesiol. - 2009; 26: 856-62. ВРАЧ 1'2014
- Katz A., Nambi S., Mather K. et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans // J. Clin. Endocrinol. Metab. - 2000; 85: 2402-10.
- Lee H., Wang G., Englander E. et al. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: Enteric distribution, ontogeny, influence of endocrine, and dietary manipulations // Endocrinology. - 2002; 143: 185-90.
- Pacifico L., Poggiogalle E., Costantino F. et al. Acylated and nonacylated ghrelin levels and their associations with insulin resistance in obese and normal weight children with metabolic syndrome // Eur. J. Endocrinol. - 2009; 161: 86170.
- Doogue M., Begg E., Moore M. et al. Metformin increases plasma ghrelin in Type 2 diabetes // Br. J. Clin. Pharmacol. - 2009; 68: 875-82.
- Varela L., Vazquez M., Cordido F. et al. Ghrelin and lipid metabolism: key partners in energy balance // J. Mol. Endocrinol. - 2011; 46: 43-63.
- Granata R., Isgaard J., Alloatti G. et al. Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone // Exper. Biol. Med. - 2011; 236: 505-14.
- Koh K., Park S., Quon M. Leptin and cardiovascular disease: response to therapeutic interventions // Circulation. - 2008; 117: 3238-49.
- Opie L. Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia // Circulation. - 2008; 117: 2172-7.
- Рichi S. Resistin down-regulates insulin-mediated glucose uptake by target tissues // Endocrine Res. - 2010; 23: 132-7.
- Kadowaki T., Yamauchi T., Kubota N. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome // J. Clin. Invest. - 2006; 116: 1784-92.
Supplementary files
